论文部分内容阅读
目的观察多西紫杉醇联合顺铂治疗晚期乳腺癌的疗效及不良反应。方法对经病理确诊的Ⅳ期乳腺癌患者41例,采用多西紫杉醇联合顺铂(TP)化疗:多西紫杉醇的剂量第1、8天为40mg/m2。第1～3天,顺铂(DDP)25mg/m2。每3周为1周期,2周期后评价疗效。结果全组患者均可评价疗效,其中完全缓解(CR)5例,部分缓解(PR)17例,稳定(SD)12例,进展(PD)7例,总有效率为53.7%(22/41)。不良反应主要为骨髓抑制,消化道反应,但均可耐受,无化疗相关性死亡。结论多西紫杉醇联合顺铂治疗晚期乳腺癌的近期疗效较好,生存时间有所延长,患者耐受性较好。
Objective To observe the efficacy and adverse reactions of docetaxel combined with cisplatin in the treatment of advanced breast cancer. Methods Forty-one patients with pathologically diagnosed stage IV breast cancer were treated with docetaxel combined with cisplatin (TP): the dose of docetaxel was 40 mg / m2 on days 1 and 8. Days 1 to 3, cisplatin (DDP) 25mg / m2. Every 3 weeks for 1 cycle, 2 cycles after the evaluation of efficacy. Results There were 5 patients with complete remission (CR), 17 with partial remission (PR), 12 with stable (SD) and 7 with progressive (PD). The total effective rate was 53.7% (22/41) ). Adverse reactions mainly bone marrow suppression, gastrointestinal reactions, but are tolerable, no chemotherapy-related deaths. Conclusion Docetaxel combined with cisplatin in the treatment of advanced breast cancer has a good short-term effect, prolonged survival time, and patients are well tolerated.